These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23664414)

  • 21. Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression.
    Sullivan GM; Ogden RT; Oquendo MA; Kumar JS; Simpson N; Huang YY; Mann JJ; Parsey RV
    Biol Psychiatry; 2009 Aug; 66(3):223-30. PubMed ID: 19278673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients.
    Wang P; Lv Q; Mao Y; Zhang C; Bao C; Sun H; Chen H; Yi Z; Cai W; Fang Y
    J Affect Disord; 2018 Mar; 228():222-228. PubMed ID: 29275155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain serotonin 1A receptor binding: relationship to peripheral blood DNA methylation, recent life stress and childhood adversity in unmedicated major depression.
    Galfalvy H; Shea E; de Vegvar J; Pantazatos S; Huang YY; Burke AK; Sublette ME; Oquendo MA; Zanderigo F; Miller JM; Mann JJ
    Br J Psychiatry; 2023 Sep; 223(3):415-421. PubMed ID: 37395098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635.
    Bhagwagar Z; Rabiner EA; Sargent PA; Grasby PM; Cowen PJ
    Mol Psychiatry; 2004 Apr; 9(4):386-92. PubMed ID: 15042104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin 1A receptor binding and treatment response in late-life depression.
    Meltzer CC; Price JC; Mathis CA; Butters MA; Ziolko SK; Moses-Kolko E; Mazumdar S; Mulsant BH; Houck PR; Lopresti BJ; Weissfeld LA; Reynolds CF
    Neuropsychopharmacology; 2004 Dec; 29(12):2258-65. PubMed ID: 15483563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment.
    Milak MS; Parsey RV; Lee L; Oquendo MA; Olvet DM; Eipper F; Malone K; Mann JJ
    Psychiatry Res; 2009 Jul; 173(1):63-70. PubMed ID: 19446443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large-scale network dynamics in neural response to emotionally negative stimuli linked to serotonin 1A binding in major depressive disorder.
    Schneck N; Tu T; Falcone HR; Miller JM; Zanderigo F; Sublette ME; Oquendo MA; Stanley B; Burke A; Ochsner K; Sajda P; John Mann J
    Mol Psychiatry; 2021 Jun; 26(6):2393-2401. PubMed ID: 32355333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toward a neuroimaging treatment selection biomarker for major depressive disorder.
    McGrath CL; Kelley ME; Holtzheimer PE; Dunlop BW; Craighead WE; Franco AR; Craddock RC; Mayberg HS
    JAMA Psychiatry; 2013 Aug; 70(8):821-9. PubMed ID: 23760393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations.
    Parsey RV; Ogden RT; Miller JM; Tin A; Hesselgrave N; Goldstein E; Mikhno A; Milak M; Zanderigo F; Sullivan GM; Oquendo MA; Mann JJ
    Biol Psychiatry; 2010 Jul; 68(2):170-8. PubMed ID: 20497898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
    Sun Y; Drevets W; Turecki G; Li QS
    Brain Behav Immun; 2020 Jul; 87():404-412. PubMed ID: 31978524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response.
    Navinés R; Martín-Santos R; Gómez-Gil E; Martínez de Osaba MJ; Imaz ML; Gastó C
    Psychoneuroendocrinology; 2007 May; 32(4):411-6. PubMed ID: 17337123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635.
    Hirvonen J; Karlsson H; Kajander J; Lepola A; Markkula J; Rasi-Hakala H; Någren K; Salminen JK; Hietala J
    Int J Neuropsychopharmacol; 2008 Jun; 11(4):465-76. PubMed ID: 17971260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging the serotonin 1A receptor using [11C]WAY100635 in healthy controls and major depression.
    Hesselgrave N; Parsey RV
    Philos Trans R Soc Lond B Biol Sci; 2013; 368(1615):20120004. PubMed ID: 23440462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
    Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cortisol Stress Response and in Vivo PET Imaging of Human Brain Serotonin 1A Receptor Binding.
    Steinberg LJ; Rubin-Falcone H; Galfalvy HC; Kaufman J; Miller JM; Sublette ME; Cooper TB; Min E; Keilp JG; Stanley BH; Oquendo MA; Ogden RT; Mann JJ
    Int J Neuropsychopharmacol; 2019 May; 22(5):329-338. PubMed ID: 30927011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic variation in brain-derived neurotrophic factor val66met allele is associated with altered serotonin-1A receptor binding in human brain.
    Lan MJ; Ogden RT; Huang YY; Oquendo MA; Sullivan GM; Miller J; Milak M; Mann JJ; Parsey RV
    Neuroimage; 2014 Jul; 94():33-39. PubMed ID: 24607934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute treatment with the antidepressant fluoxetine internalizes 5-HT1A autoreceptors and reduces the in vivo binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rat.
    Riad M; Zimmer L; Rbah L; Watkins KC; Hamon M; Descarries L
    J Neurosci; 2004 Jun; 24(23):5420-6. PubMed ID: 15190115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.